#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome

1 1 1 1

What is this study about?

This clinical trial is focused on studying the safety and effectiveness of a treatment for people with Chronic Lymphocytic Leukemia (CLL) and Richter’s Syndrome. The treatment being tested is called Epcoritamab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific targets in the body, such as cancer cells. In this study, Epcoritamab is being tested alone and in combination with other medications, including Venetoclax and Lenalidomide. Venetoclax is a medication that helps to kill cancer cells by blocking a protein that allows them to survive, while Lenalidomide is used to help the immune system attack cancer cells.

The purpose of the study is to find the best dose of Epcoritamab and to see how well it works in treating these conditions. Participants will receive Epcoritamab either by itself or in combination with Venetoclax or Lenalidomide, depending on their specific condition. The study will also look at how safe the treatment is and how well it is tolerated by participants. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, participants will be monitored closely to assess the treatment’s effects on their condition and any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using Epcoritamab for treating Chronic Lymphocytic Leukemia and Richter’s Syndrome. This research could lead to new treatment options for people with these challenging conditions.

1 initial treatment phase

The study begins with the administration of epcoritamab as a monotherapy. This involves receiving the medication through a subcutaneous injection. The goal is to determine the appropriate dosage and assess safety.

During this phase, the frequency and duration of administration will be determined based on individual response and tolerance.

2 combination therapy with venetoclax

Following the initial phase, epcoritamab is combined with venetoclax, which is taken orally. The dosage of venetoclax is 400 mg.

The combination aims to evaluate the safety and effectiveness of the two medications together. The duration of this phase depends on the response to treatment.

3 expansion therapy with lenalidomide

For patients with Richter’s Syndrome, epcoritamab is combined with lenalidomide. This phase assesses the preliminary effects of the combination.

Lenalidomide is administered orally, and the treatment continues as long as it is deemed beneficial.

4 monitoring and follow-up

Throughout the trial, regular monitoring is conducted to assess the safety and effectiveness of the treatments. This includes routine blood tests and imaging studies.

Follow-up visits are scheduled to track progress and manage any side effects that may occur.

Who Can Join the Study?

  • The person must sign an informed consent form before any screening procedures.
  • The person must be at least 18 years old.
  • The person must have an ECOG performance status score of 0, 1, or 2. This is a scale that measures how well a person can perform daily activities.
  • There must be evidence of CD20 positivity in a sample that represents the disease, such as a tumor biopsy, blood sample, or bone marrow sample.
  • The person must have acceptable laboratory test results.
  • A woman who can have children must agree to use effective birth control during the trial and for 12 months after the last dose of the study drug.
  • A woman who can have children must have a negative pregnancy test before starting the trial and before each treatment cycle.
  • A woman must agree not to donate eggs for assisted reproduction during the trial and for 12 months after the last treatment.
  • A man who is sexually active with a woman who can have children and has not had a vasectomy must agree to use a barrier method of birth control, like a condom.
  • For those with R/R CLL (a type of leukemia), the person must have active disease that needs treatment and must have received at least two prior treatments.
  • The person must have a diagnosis of CLL/SLL that meets specific criteria.
  • The person must take preventive measures for TLS (tumor lysis syndrome), a condition that can occur when cancer cells break down quickly.
  • For those with Richter’s Syndrome, the person must have measurable disease as determined by specific scans and must provide a required tumor tissue sample.
  • For those eligible for Lenalidomide Combination Therapy, the person must have a specific type of tumor and a history of CLL/SLL, be ineligible for certain other treatments, and be eligible for lenalidomide.
  • For those eligible for R-CHOP Combination Therapy, the person must have a specific type of tumor and a history of CLL/SLL and be eligible to receive R-CHOP treatment.
  • For those eligible for Venetoclax Combination Therapy, the person must have active CLL/SLL disease that needs treatment.

Who Cannot Join the Study?

  • Patients who have a different type of cancer than Chronic Lymphocytic Leukemia (CLL) cannot participate. CLL is a type of cancer that affects the blood and bone marrow.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
  • Patients who have other serious health conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate, as the study may affect the baby.
  • Patients who have participated in another clinical trial recently may not be eligible to participate.
  • Patients who have allergies or reactions to the study medication or similar medications cannot participate.
  • Patients who are unable to provide informed consent, which means they cannot understand and agree to the study details, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Katholieke Universiteit te Leuven Leuven Belgium
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
University Hospital Of Clermont-Ferrand Clermont Ferrand France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France

Other Sites

Site Name City Country Status
University Hospital Ostrava Ostrava Czechia
Ospedale San Raffaele S.r.l. Milan Italy
Fakultni Nemocnice Hradec Kralove Novy Hradec Kralove Czechia
Sygehus Lillebaelt Vejle Sygehus Vejle Denmark
Hopital Beaujon Clichy France
L’Hopital Prive Du Confluent Nantes France
Az St-Jan Brugge-Oostende A.V. Brugge Belgium
University Hospital Olomouc Olomouc Czechia
Zealand University Hospital Roskilde Denmark
Uwgudhgqtk Hkwsbbow Cttpjta Cologne Germany
Offyrm Uwhhmnofib Hyaemvbw Odense Denmark
Irjswymu Rhalmtfsz Pot Lc Shaktd Dap Tmuftb Dfsj Auzedbp Ipow Svvulv Meldola Italy
Adgfhwhmk Upq Amsterdam The Netherlands
Utkpenqscgqd Meykjec Cvkuahi Uiuqfac Utrecht The Netherlands
Hvwsnwzt Ctddcx Dr Bklcgyonl Barcelona Spain
Fwzhvhax Nudwqrehu Bhmt Brno Czechia
Hpioubak Ulodysgcijhms Fhybihosz Jkvvjog Dang Madrid Spain
Cidovx Hgkkfprfynj Uuovsolmkwxoz Db Moeeaymdnzr Montpellier France
Aduimwk Oytsgcjpbea Ubqisrxkbwjgp Cekzkuzivydn Dwlgf Sokjpq E Dudiq Scowouy Dt Teuntu Turin Italy
Amsdozy Ulodmjulin Hlvlctvd Aalborg Denmark
Caxc Dh Niwob Vandoeuvre Les Nancy France
Axggiox Omlkpyzkmaozgngsdosamophv Mlcwgicy Dzlbw Clzlni Novara Italy
Vttvqhenh Fbmudvrr Nyirbqmcm V Pabgo Prague Czechia
Ucqjvfefck Hpcfxunk Mvsbcgmefd Maastricht The Netherlands
Rcnzqlzilyquul Copenhagen Denmark
Aisjmuy Ueqrh Sbqaysbpm Lbrxue Dy Bwdtywg Bologna Italy
Hovvehzc Dd Lh Sgdra Cqpu I Suqv Pyf Barcelona Spain
Ufkvhtegdz Dyqqc Szgto Da Rwzn Lh Slvtxhvk Rome Italy
Ifwxllyu ftbl Khdaycssv Tpqyiknesfulkyomrgp uzb Ifobvmxkmavd Uab gcyep Ulm Germany
Umraohapjrol Zpycktnlhx Gdld Gent Belgium
Ucymkpyuamoq Mairkln Cphgniz Gkuybzatn Groningen The Netherlands
Uqkpeqtfvijsyijwwtdsa Skfkfnygvvnslzzzak Atf Kiel Germany
Inaygidu Cvgxne Dqdjpnwahikqkzjvt L'hospitalet De Llobregat Spain
Udzpufsnkt Dlhdw Sxodw Dp Baiassi Brescia Italy
Ugwugqjfymldxtbgs Dumom Seyru Dr Fpcqjnv Ferrara Italy
Pkbqhq Htmiwxlkrob Sei z orez Katowice Poland
Avslvae Snc z ovjy Poznan Poland
Iaeclpef Df Cqipefpt Fckepvhngw Dwj Ptyymeln Pvx Lzholmubqu Ittyf Candiolo Italy
Aqmufs Ueicabexvc Hewjrkwl Aarhus Denmark
Pyklud Susy Skorzewo Poland
Ancvcb Sggjdwvwtr Zkewjswccm Dordrecht The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
25.11.2020
Czechia Czechia
Not recruiting
25.11.2020
Denmark Denmark
Not recruiting
25.11.2020
France France
Not recruiting
25.11.2020
Germany Germany
Not recruiting
25.11.2020
Italy Italy
Not recruiting
25.11.2020
Poland Poland
Not recruiting
25.11.2020
Spain Spain
Not recruiting
25.11.2020
The Netherlands The Netherlands
Not recruiting
25.11.2020

Trial locations

Investigated Drugs:

Epcoritamab is a medication being studied for its potential to treat certain types of blood cancers, specifically relapsed or refractory chronic lymphocytic leukemia (R/R CLL) and Richter’s syndrome (RS). It is designed to help the immune system target and destroy cancer cells. The trial aims to find the best dose of epcoritamab and to evaluate its safety and effectiveness when used alone or in combination with other treatments.

Venetoclax is another medication involved in the trial, used in combination with epcoritamab for treating R/R CLL. Venetoclax works by helping to kill cancer cells and is being tested to see how well it works with epcoritamab to improve treatment outcomes.

Lenalidomide is being tested in combination with epcoritamab for treating Richter’s syndrome. Lenalidomide is known to modify the immune system and may help enhance the effects of epcoritamab in fighting cancer cells.

R-CHOP is a combination therapy that includes several drugs used to treat certain types of lymphoma. In this trial, R-CHOP is combined with epcoritamab to assess its effectiveness in treating Richter’s syndrome. The goal is to see if adding epcoritamab can improve the treatment results of the standard R-CHOP regimen.

Chronic Lymphocytic Leukemia – Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It is characterized by the production of an excessive number of abnormal white blood cells called lymphocytes. These abnormal cells accumulate over time, crowding out healthy blood cells and impairing the immune system. CLL typically progresses slowly, and many individuals may not experience symptoms for years. As the disease advances, symptoms such as fatigue, swollen lymph nodes, and frequent infections may occur. The progression of CLL can vary greatly among individuals, with some experiencing a more aggressive form of the disease.

Trial ID:
2023-504828-25-00
Protocol code:
GCT3013-03
NCT ID:
NCT04623541
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Evaluating the efficacy of pirtobrutinib and epcoritamab in patients with untreated Richter transformation of chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Denmark Germany Ireland The Netherlands

  • A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Italy Spain